Clinical trials
Acute Hospitalization clinical trials
Below are recruiting acute hospitalization clinical trials, each written for real people, not researchers. We’re tracking 987 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07023679Recruiting
Stellate ganglion shot with morphine for heart attack patients
This study tests if a painkiller (morphine) injected near certain neck nerves can reduce damage to the heart muscle during a heart attack procedure. It is for people having a specific type of heart attack and who will get a stent to open the blocked artery.
HefeiAges 18 years+ - NCT07115511Recruiting
Surgical rescue after failed clot removal for stroke
This trial tests a surgical rescue treatment for people who have had a major stroke from a large artery blockage, but the standard clot removal procedure (thrombectomy) did not fully open the artery. The goal is to see if combining surgery with the earlier procedure can improve outcomes.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07118748Recruiting
Pharmacy antibiotics for cystitis with decision support tool
This trial tests a new way for women to get antibiotics for simple bladder infections (cystitis) directly from a pharmacy, without needing to see a doctor first. A computer tool helps the pharmacist make sure it is safe. This could make treatment faster and easier for you.
Aire-sur-l'AdourAges 18–65 - NCT07211529Recruiting
Nerve block during chest surgery to reduce complications
This trial tests whether a numbing injection near the spine (paravertebral block) given during keyhole chest surgery can lower the risk of problems after surgery. It might help patients recover more comfortably.
Wuhan, HubeiAges 18–80 - NCT07266675Recruiting
Recovery after cardiogenic shock study
This trial looks at what happens to people after they survive a serious heart condition called cardiogenic shock, where the heart suddenly can't pump enough blood. Researchers want to understand recovery and improve care for survivors.
TaipeiAges 18 years+ - NCT07304232RecruitingPhase 2
Chidamide after stem cell transplant for AML
This trial tests a drug called chidamide (Cidabenamide) as maintenance therapy after a stem cell transplant for people with intermediate or high-risk AML. The goal is to see if it helps prevent the leukemia from coming back.
Shijiazhuang, HebeiAges 18–75 - NCT03300492RecruitingPhase 1/Phase 2
Natural killer cell treatment after a half-matched stem cell transplant
This early trial studies adding special immune cells called “natural killer cells” after a half-matched stem cell transplant for AML or MDS. The goal is to see if this approach improves outcomes and safety when there is no fully matched donor available.
BaselAges 18 years+ - NCT07439757Recruiting
Using AI to Guide Care for Pancreatic Conditions
This study uses artificial intelligence (AI) to help doctors make better decisions for people with suspected pancreatic conditions. If you are already getting a special CT scan, the AI will analyze the images to see if it can improve diagnosis and treatment planning.
ShanghaiAges 18–80 - NCT07537257Enrolling by invitationPhase 2/Phase 3
Venetoclax plus chemotherapy vs chemotherapy alone for acute myeloid leukemia
This trial tests whether adding venetoclax (a targeted drug) to standard chemotherapy helps patients with acute myeloid leukemia (a blood cancer) who have responded well to initial treatment stay cancer-free longer. You would receive the combination or standard therapy alone to see which works better.
Guangzhou, GuangdongAges 18–65 - NCT03601702Recruiting
EmboTrap device for large stroke blockages
This trial studies whether a specific clot-removal device (EmboTrap II) works well for acute stroke caused by a large artery blockage. It may help restore blood flow faster in people who have certain scan patterns and can be treated within 12 hours.
MilanAges 18 years+ - NCT06427330RecruitingPhase 2
Low-Dose Inotuzumab After Transplant to Prevent Leukemia Relapse
This trial tests whether a low dose of a targeted drug called inotuzumab ozogamicin, given after a stem cell transplant, can help prevent acute lymphoblastic leukemia from coming back. It is for people who have already had a transplant and are at high risk for relapse.
TianjinAges 18 years+ - NCT06458257Recruiting
Stem cell transplant for high-risk AML with CEBPA mutation
This trial tests whether a stem cell transplant from a donor can help people with a specific type of acute myeloid leukemia (AML) that has a high risk of coming back. It is for patients who have the CEBPA gene mutation and other high-risk features.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT06622525Recruiting
Baking soda to prevent kidney damage from heatstroke
This trial tests if giving sodium bicarbonate (baking soda) can protect the kidneys in people with severe heatstroke, which can cause muscle breakdown and kidney injury.
Mexicali, Estado de Baja CaliforniaAges 18 years+ - NCT07290751RecruitingPhase 4
Adding tirofiban to clot-busting for stroke patients
This trial tests whether adding a second medicine (tirofiban) to standard clot-busting treatment can help people who are not improving after the first hour. It is for people with a moderate to severe stroke who are not candidates for a clot-removal procedure.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07512700RecruitingPhase 2
New drug combination versus standard therapy for acute monocytic leukemia
This study tests whether a newer drug called venetoclax, combined with a chemotherapy regimen called CACAG, works better than the standard "3+7" chemotherapy for treating acute monocytic leukemia (a blood cancer). The goal is to help patients achieve remission and improve survival.
BeijingAges 14–60 - NCT07584889RecruitingPhase 1/Phase 2
CAR-T Cell Therapy for Relapsed Blood Cancers
This trial tests a new type of immune cell therapy (CAR-T cells) designed to fight blood cancers that have come back or stopped responding to standard treatments. The therapy uses your own immune cells, which are modified in a lab to better recognize and attack cancer cells.
Shenzhen, Other (Non U.s.)Ages 18–75 - NCT07682298Recruiting
Measuring leftover fluid in hospitalized heart failure patients
This study looks at how well we can measure leftover fluid in the body in people hospitalized for heart failure with fluid overload. It aims to help doctors better manage treatment and improve recovery.
AarhusAges 18 years+ - NCT07106749RecruitingPhase 1
CD180 car T cells for blood cancers that came back
This trial tests a new CAR T cell therapy that targets a protein called CD180 on cancer cells. It is for people with certain types of relapsed or refractory leukemia or lymphoma that has not responded to standard treatments.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT07569939Recruiting
Treatment options for sore throat from viral infection
This study tests different treatments to help ease sore throat pain and symptoms caused by viral throat infections. It aims to find the best way to relieve discomfort when you have pharyngitis, tonsillitis, or a viral sore throat that started recently.
Clermont-FerrandAges 18–70 - NCT06201247RecruitingEarly Phase 1
CD123-targeted immune cell therapy for relapsed/refractory AML
This early-phase trial tests an 'off-the-shelf' immune cell treatment (CAR-NK cells) that targets a protein called CD123 on leukemia cells. It's for people with AML that has returned or hasn't responded to standard treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06389305Recruiting
CIK cell therapy for B-cell leukemia after CAR-T failure
This trial tests CIK immune cells for children and young adults with B-cell acute lymphoblastic leukemia that stopped responding to CAR-T cell therapy within 6 months. The goal is to see if CIK cells can help when CAR-T cells no longer work.
Beijing, Beijing MunicipalityAges 1–39 - NCT05905146Recruiting
Personalized opioid plan to shorten treatment time
This trial tests whether a personalized medication plan can help patients with short-term, non-cancer muscle or joint pain need strong opioid medicine for a shorter time. It’s aimed at improving how long treatment lasts while still managing pain.
LilleAges 18 years+ - NCT06056752RecruitingPhase 1
CAR-T cell therapy for B-cell acute lymphoblastic leukemia
This trial tests a new cell therapy (QH103) for people with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to treatment. The therapy uses specially modified immune cells to find and kill cancer cells that have a protein called CD19 on their surface.
Hefei, AnhuiAges 14 years+ - NCT06287112Recruiting
Preventing gallbladder inflammation after bile duct drainage
This study tests whether a new drainage method can help prevent acute cholecystitis (inflammation of the gallbladder) in people who need a bile duct procedure. If you are at risk for gallbladder issues, this approach might reduce complications.
SeoulAges 19 years+
Hear when a new Acute Hospitalization trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for acute hospitalization?
- Yes. Clin2 currently lists 987 recruiting acute hospitalization studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a acute hospitalization trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a acute hospitalization trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.